Cancer / Oncology
Hox Therapeutics Ltd, a pioneering biotechnology company dedicated to developing targeted cancer therapies, and Vernalis (R&D) Ltd, a renowned subsidia...
February 22, 2024 | News
Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FR&alp...
February 16, 2024 | News
The cancer situation in Africa is alarming, with 1.1 million new cases and 700,000 deaths in 2020. Breast, cervical, prostate, colorectal, and live...
February 04, 2024 | News
Dr. Jianmin Fang, CEO of RemeGen, commented, "Cancer is the common enemy of mankind, and at RemeGen we feel a strong sense of responsibility and missi...
February 02, 2024 | News
The lead investor is China Development Industrial Bank (CDIB), with significant contributions from Taian Venture Capital, Maxpro and the National Developme...
February 01, 2024 | News
Pathos AI, Inc. announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc., successfully completed its tender offer to acquire all outs...
January 29, 2024 | News
KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in...
January 05, 2024 | News
The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...
December 21, 2023 | News
Report highlights fundamental shift in treatment for cancer, from a terminal to a chronic disease that can be treated and managed Expl...
December 04, 2023 | News
Ying Ying Yeoh, a key figure at Roche, shares insights into the transformative impact of public-private partnerships (PPPs) on healthcare i...
November 29, 2023 | News
Astellas Pharma Inc. announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Appl...
November 27, 2023 | News
Despite the significant transformation of the cancer treatment landscape by immunotherapies, long-term remissions only occur in 15-20% of cancer patients. ...
November 27, 2023 | News
Gilead and Kite Oncology, announced that two poster presentations, covering results from two of the largest real-world analyses, will be presented during t...
November 03, 2023 | News
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value R...
October 10, 2023 | News
Most Read
Bio Jobs
News
Editor Picks